Who Paid My Doc
Melena Bellin
Pediatric Endocrinology Minneapolis, MN Medical Doctor
NPI 1124219043 CMS profile 1221016
2450 Riverside Ave, Minneapolis, MN 55454
General payments
$56,256
Research payments
$1,593
Ownership & investment interest
$0
Research they led as principal investigator
$93,006
Through program year 2025, Melena Bellin of Minneapolis, MN is reported in the CMS Open Payments database as having received $56,256 across 80 general payments and $1,593 in research payments paid to them. Separately, studies naming them as principal investigator received $93,006 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21,687 | 35 | |
| 2024 | General | $27,246 | 31 | |
| 2023 | General | $5,680 | 8 | |
| 2022 | General | $1,320 | 2 | |
| 2021 | General | $13 | 1 | |
| 2019 | General | $310 | 3 | |
| 2019 | Research | $1,593 | 1 |
Beside peers
- Melena Bellin
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Melena Bellin were reported at $21,687. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Melena Bellin | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $310 | $196 | $68–$845 | $163 |
| 2020 | $0 | $124 | $37–$722 | $114 |
| 2021 | $13 | $134 | $35–$691 | $132 |
| 2022 | $1,320 | $177 | $47–$726 | $149 |
| 2023 | $5,680 | $236 | $75–$887 | $160 |
| 2024 | $27,246 | $259 | $91–$979 | $164 |
| 2025 | $21,687 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
225
Drug cost
$164,130
Branded share of claims
56.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Creon Lipase/Protease/Amylase | Brand | 38 | $124,132 | |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | Brand | 19 | $22,793 | |
| Mycophenolic Acid Mycophenolate Sodium | Brand | 25 | $7,700 | |
| Tacrolimus | Generic | 83 | $5,200 | |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | Brand | 13 | $1,499 | |
| Mycophenolate Mofetil | Generic | 14 | $1,468 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 16 | $1,238 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 17 | $100 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 8 billing codesPaid by Medicare
$2,178
Medicare patients
15
Services billed
33
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Diabetes | 75% | |
| Heart failure | 0% | |
| Cancer | 0% | |
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
81 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in Minnesota
Bradley Miller
Pediatric Endocrinology · Minneapolis, MN
Antoinette Moran
Pediatric Endocrinology · Minneapolis, MN
Mary Abuzzahab
Pediatric Endocrinology · Saint Paul, MN
Amy Criego
Pediatric Endocrinology · St Louis Park, MN
Ana Creo
Pediatric Endocrinology · Rochester, MN
Laura Gandrud Pickett
Pediatric Endocrinology · St Louis Park, MN
Related records
Pediatric Endocrinology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.